Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men


DOI: First published online: 6 August 2015

Professional guidelines recommend testosterone replacement therapy (TRT) in patients with signs and symptoms of hypogonadism and documented evidence of low testosterone (T) levels.1 The diagnosis of late-onset hypogonadism is on the rise with estimates that nearly 2.4 million men aged 40–69 suffer from hypogonadism in the USA.2 Even though late-onset hypogonadism is not a universally accepted concept, and FDA has advised against T supplementation in men on the basis of age alone. However, in the last decade there has been a nearly 400% increase in the number of TRT prescriptions creating a billion dollar market.3 With such widespread and ever increasing use of TRT, there has been growing concern regarding its effect on mortality and cardiovascular (CV) outcomes. Read More